Category
Biotech
Zymeworks Stock Skyrockets After Cancer Breakthrough — But What’s Next?
Zymeworks soared 34% after its partnered drug Ziihera posted strong Phase 3 data, with Jazz Pharmaceuticals showing it improved outcomes in a tough cancer — a breakthrough moment for the company.
Pacira BioSciences Pops As Activist Investor Calls For Sale — What You Need To Know!
Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist pressure follows solid EXPAREL growth but weak stock performance.
Nektar Therapeutics Gains New Life On Buyout Rumors & Atopic Dermatitis Breakthrough
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds.
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here's Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the pharma giant is preparing for its next leap: a daily oral pill named orforglipron.
BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions
BioNTech’s recent $1.25 billion all-stock acquisition of former rival CureVac marks a definitive shift in strategy—away from COVID-19 vaccine reliance and toward building a diversified cancer portfolio.
Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?
Bristol Myers has inked a transformative partnership for BNT327, a bispecific PD-L1/VEGF-A antibody developed by BioNTech, with a $1.5 billion upfront payment and additional milestone-based payouts stretching through 2028.
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Eli Lilly has agreed to acquire SiteOne Therapeutics, a clinical-stage biotech specializing in small molecule inhibitors of sodium channels involved in pain signal transmission.
Is Cytokinetics The Next Big Takeover Target? Here's What You Need to Know!
Cytokinetics has recently surged amid renewed takeover speculation as reported on a Betaville "uncooked" alert, with multiple large pharmaceutical firms reportedly showing interest in acquiring it.
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
According to a Betaville "uncooked" alert, an unidentified European pharmaceutical company is reportedly exploring a bid for Arcutis Biotherapeutics.
Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!
Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with a 4% surge in its stock price amidst the speculation.
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer.
Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen
Maravai LifeSciences has recently caught the attention of Repligen as a potential acquisition target, marking it as a significant player in the biotech space.
Travere's Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!
Travere Therapeutics' completion of a successful pre-NDA meeting with the U.S. FDA for Filspari in IgA nephropathy has sent its stock skyrocketing by more than 30% in a single trading session.
OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology
OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the domain of ophthalmic diseases and is expected to see its core drug candidate in Phase 2 of clinical trials in the very near future.
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
Shelton, Connecticut — March 2, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported today on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is pre
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 – Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
SHELTON, CONNECTICUT – February 16, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2021 with the Securities and Exchange Commission.
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan
Shelton, CT – January 27, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform, today discusses the current developments in the COVID-19 pandemic and the Company’s exciting accomplishments related to it. “
Applied UV, Inc. to Patent a System to Neutralize Pathogens on Physical Surfaces
Hot off the press! AppliedUV, Inc, (NasdaqCM:AUVI) issues a press release today to announce their pending patent for sanitizing commonly used surfaces in public spaces. disinfection technology is hear to stay. Read the announcement after the break. Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Filing of U.S. Patent Application for a System to Neut
Lifequest Signs MOU with Purecycle Inovatif to Establish a Joint Venture in Turkey
Lifequest Subsidiary Biopipe Global Signs Memorandum of Understanding with Purecycle Inovatif to Establish a Joint Venture to Market 100% Sludge Free Biological Sewage Wastewater Treatment Systems in Turkey RIDGEFIELD PARK, NEW JERSEY, SEPTEMBER 24, 2020. LIFEQUEST WORLD CORP (LQWC ) subsidiary Biopipe Global, which developed the world’s only highly scal
Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Receipt of Purchase Order for Airocide™ Air Quality-Improvement™ System from Dubai Creek Golf & Yacht Club Resort
Mount Vernon, NY, September 22, 2020 – Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), an infection prevention technology company that applies the power of narrow-range ultra violet light (“UVC”) utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc.
Applied UV, Inc. Subsidiary, SteriLumen, Inc. Installs First Ultraviolet Light Disinfecting Devices at Mt. Sinai St. Luke’s Hospital as Part of Evaluation Study
Mount Vernon, NY, September 17, 2020 – Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), an infection prevention technology company that applies the power of narrow-range ultra violet light (“UVC”) utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc.
$3,500,000 Initial Order for FDA-Registered, Premium Hand Sanitizer Catapults SkinScience Labs, a Pending Accretive Acquisition of Pressure BioSciences, Into the Multi-Billion Dollar Hand Sanitizer Market
SkinScience Labs, Creator of Award-Winning Dr. Denese Skin Care & Anti-Aging Product Lines, Enters Hand Sanitizer Market with Proprietary Formula Developed by Founder Adrienne Denese, MD., Ph.D.
NanoViricides: Drug Candidates Show Fantastic Results In Animal Model
In our earlier pieces, we have provided an in-depth coverage of the promising biopharma smallcap NanoViricides Inc. (NYSE American: NNVC) and its huge potential within the anti-viral medications space. The company has rapidly advancement with respect to the drug development process of its COVID-19 drug and a big role was played by CEO Dr. Anil ...
Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners
South Easton, MA, May 14, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announce
Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.
South Easton, MA, April 30, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announ
Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform
New York, NY – March 11, 2020 – Parallax Health Sciences, Inc.(OTCQB: PRLX) ("Parallax" or the "Company"), an outcome-driven connected healthcare company, today announced its wholly owned subsidiary Parallax Diagnostics, Inc. will execute a partnership strategy to develop, acquire or license monoclonal and polyclonal antibodies for the creation o
Moderna Gains 18% on positive CMV vaccine data
Moderna (NASDAQ:MRNA) gained 16% in heavy after-hours buying and selling exercise at the moment. The firm posted the positive Phase 1 data for its vaccine candidate for Cytomegalovirus. The Company additionally says that It additionally says the primary participant was dosed within the Phase 2 dose-confirmation research. Phase 2 interim data at three months,
NanoKnife FDA Approval Is The Highlight Of An Otherwise Tepid AngioDynamics Quarter
Latham, New York: AngioDynamics, Inc. (NASDAQ:ANGO) is a number one supplier of modern, minimally invasive medical units utilized by skilled healthcare suppliers for vascular entry, peripheral vascular illness, and oncology. It just lately reported its monetary outcomes for the third quarter of the fiscal 12 months 2019 ending 28th February 19 whereby the co
Lexicon’s Volatility Could Be Your Friend After The Zynquista Rejection
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is an organization identified for locating novel drug targets and drug candidates developed from state-of-the-art medicinal chemistry and proprietary gene. The firm lately produced a superb outcome beating Wall Street expectations with the administration anticipating a 20% income development in 2019, pushed by Euro
Aerie Pharmaceuticals Delivers Mixed Result; Focus On International Expansion
Durhan, NC: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a scientific stage pharmaceutical firm targeted on offering therapies for the therapy of eye-related illnesses, launched its quarterly outcomes for the interval ended December 31,2018. The firm delivered its third consecutive blended outcome with a income beat however with an earnings miss. The administr
Tackling triple-negative breast cancer by blocking 2 key survival pathways
[ad_1] Triple-negative breast cancer is the hardest type of the illness to deal with as a result of it lacks estrogen and progesterone receptors and it doesn’t over-express HER2, making it unresponsive to focused therapies. Now, a workforce of researchers led by Princeton University have promising early proof {that a} recombinant protein may block two ...
J&J takes stake in Locus’ CRISPR-based ‘Pac-Man’ antimicrobials
[ad_1] Just over a yr after its first-round financing, CRISPR firm Locus Biosciences has signed up Johnson & Johnson as its first massive pharma accomplice and pocketed a $20 million upfront payment. While most CRISPR firms are taking a look at making use of the CRISPR-Cas9 gene-editing know-how to human illnesses, Locus is taking a ...
LHC Group to Present at 37th Annual J.P. Morgan Healthcare Conference Nasdaq:LHCG
[ad_1] LAFAYETTE, La., Jan. 03, 2019 (GLOBE NEWSWIRE) — LHC Group, Inc. (NASDAQ: LHCG) introduced as we speak that the Company is presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019. The presentation will start at 7:30 a.m. Pacific time, adopted by a separate Q&A session at ...
Ex-Novartis Oncology CEO Barrett joins UroGen
[ad_1] Ex-Novartis Oncology CEO Liz Barrett has joined UroGen Pharma. Barrett is taking on as CEO of the uro-oncology specialist at a time when it's engaged on a rolling NDA that might result in its first drug approval. Barrett ended a 10-month stint as CEO of Novartis Oncology shortly earlier than Christmas after deciding that ...
Amedisys to Present at the 37th Annual J.P. Morgan Healthcare Conference Nasdaq:AMED
[ad_1] BATON ROUGE, La., Jan. 02, 2019 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), one among America's main residence health and hospice care corporations, right this moment introduced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Ja
.jpg&w=3840&q=75)
After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal
[ad_1] French Big Pharma Sanofi is strolling away from a coronary heart drug illness pact with MyoKardia forward of knowledge readouts coming later this yr. In typical biotech PR spin, MyoKardia labored the information as it “regaining the rights back” to those packages, however in actuality, Sanofi wished out of the pact that it initially ...
Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference Nasdaq:OXFD
[ad_1] OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a world, high-growth diagnostics firm, right now introduced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 3:00 p.m
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline
[ad_1] Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline. Staten has quietly established itself in the Dutch biotech scene over the past four years. Over that time, ...
Doug Disraeli D.D.S. Offers Tips on How to Stick to Your Daily Flossing Resolutions
[ad_1] SAN DIEGO, Dec. 28, 2018 (GLOBE NEWSWIRE) — With the vacation season amongst us, Dr. Doug Disraeli is aware of how arduous it may be sticking to a healthy dental regime. Doug Disraeli D.D.S. provides tips for sticking to that flossing decision in 2019 and past. Flossing removes plaque in addition to stopping the ...
Harpoon files $86M IPO to help fund its T-cell engager platform
[ad_1] Fresh off elevating $70 million by a collection C spherical simply over a month in the past, Harpoon Therapeutics introduced it should go public with an $86.25 million IPO to additional help its portfolio of early-stage T-cell engagers geared toward strong tumors. The South San Francisco-based firm filed confidentially with the SEC in late ...
Innovent buys Chinese rights to Incyte drugs for $40M upfront
[ad_1] Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in growth at Incyte. The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs which might be in section 2 and 3 testing within the West. China’s Innovent put ...
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
[ad_1] Australian biotech Imugene says its HER2 vaccine hit the mark in a part 1b trial, establishing a part 2 examine that may start recruiting sufferers in the brand new yr. The first tranche of data from the 14-patient trial comes from the primary 10 evaluable topics who got the HER-Vaxx vaccine at three doses ...
Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
[ad_1] Entrada Therapeutics has debuted with a $59 million sequence A and a plan to ship biologic therapies intracellularly to deal with uncommon and deadly monogenic illnesses. The Boston-based firm will start by tasking its delivery platform for enzyme substitute therapies, protein-protein interplay inhibitors and nucleic acids—together with in an undisclo
Idorsia's selatogrel hits goals in phase 2 cardiovascular trials
[ad_1] Idorsia's P2Y12 receptor antagonist selatogrel has considerably inhibited platelet aggregation in two phase 2 trials. The major endpoint successes in sufferers with secure coronary artery illness (CAD) or acute myocardial infarction (AMI) set Idorsia as much as plan the initiation of a phase 3 examine. Switzerland’s Idorsia, which spun out of Actelion
Sophiris slides on prostate cancer data but vows to press on
[ad_1] Sophiris Bio is adamant that it's going to advance its lead drug topsalysin into section 3 testing, after a second dose confirmed no extra profit in a prostate cancer trial. The firm insists that the midstage data offered after a single administration of the drug is sufficient to warrant a late-stage program. Shares within ...
Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Stockholm Stock Exchange:OV
[ad_1] Company NewsOncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Hørsholm, Denmark and Cambridge, MA, US, December 18, 2018 – Oncology Venture A/S (“OV” or the Company) right this moment introduced that the US Food and Drug Administration, FDA has responded positively on questions posed ...
Lexicon pain drug advances after clearing early clinical test
[ad_1] A part 1a trial of Lexicon Pharmaceuticals’ LX9211 has met its main aims. The examine discovered the AAK1 inhibitor was effectively tolerated, teeing Lexicon as much as advance the neuropathic pain prospect. Lexicon licensed LX9211 from Bristol-Myers Squibb in 2016 after working with the Big Pharma to characterize the AAK1 goal via a neuroscience ...
Roivant strikes broad pipeline pact with Daiichi
[ad_1] Roivant has secured an choice to license a stream of medication from Daiichi Sankyo. The deal is the primary time Roivant has fashioned a framework to facilitate the continued in-licensing of medication from an organization relatively than picked up belongings on an advert hoc foundation. Through the deal, Roivant has gained the choice to ...
International Isotopes Inc. (OTCBB:INIS) is Attracting Smart Money
[ad_1] In a simply printed Form 13, filed with the US Securities and Exchange Commission (SEC), International Isotopes Inc. (OTCBB:INIS) reported that Kennerman Associates, Inc. has picked up 195,304,771 of frequent stock as of 2017-05-01. The acquisition brings the combination quantity owned by Kennerman Associates, Inc. to a complete of 195,304,771 represe
Communique from EGM in Oncology Venture A/S Stockholm Stock Exchange:OV
[ad_1] Company Announcement Communique from EGM in Oncology Venture A/S Hoersholm, Denmark, December 18, 2018 – at this time, a rare basic assembly in Oncology Venture A/S was held. A abstract of the resolutions adopted follows under. All resolutions had been adopted with the required majority of votes. Election of latest members of the ...
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris
[ad_1] Chugai has the optimistic part 3 knowledge it must file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum dysfunction (NMOSD), a rare autoimmune illness, subsequent yr. The Japanese drugmaker now has two optimistic part 3 research backing the efficacy and security of the antibody in the dysfunction, which causes irrita
Here's Who Just Picked Up Photomedex Inc (NASDAQ:PHMD) Shares
[ad_1] In a simply revealed Form 13, filed with the US Securities and Exchange Commission (SEC), Photomedex Inc (NASDAQ:PHMD) reported that Pell Lewis C has picked up 424,064 of frequent stock as of 2017-05-01. The acquisition brings the mixture quantity owned by Pell Lewis C to a complete of 424,064 representing lower than 9.7% stake ...
DBV pulls peanut allergy filing after FDA faults data details
[ad_1] DBV Technologies has withdrawn the filing for FDA approval of its peanut allergy remedy. The French biotech pulled the BLA after talks with the company revealed gaps within the manufacturing and quality-control sections of the filing. Doubts about DBV’s potential to get its peanut allergy therapy, Viaskin Peanut, previous the FDA emerged final yr ...
Cara Therapeutics Continues to Climb (NASDAQ:CARA)
[ad_1] We suppose Cara Therapeutics (NASDAQ: CARA), a boutique “clinical stage” biotech/biopharma firm which develops novel compounds (together with hashish derived chemical compounds) for neuropathic ache is worthy of a detailed look. Cannabis regulation has been enjoyable each globally and within the United States and this influences our stance on CARA sto
The Right Way to Address Prescription Drug Costs
[ad_1] Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to define for policymakers the very best strategy for tackling the affordability of pharmaceuticals. “As policy professionals from different sides of the aisle, we believe there is a right way to address these issues and a ...
NRC Health Trends Report Uncovers the Forces Shaping Healthcare Consumerism Nasdaq:NRC
[ad_1] LINCOLN, Neb., Dec. 21, 2018 (GLOBE NEWSWIRE) — NRC Health, the main supplier of in-depth buyer intelligence in healthcare, at this time launched its new 2019 Healthcare Consumer Report. Based on insights from over one million healthcare customers nationwide, coupled with insights from revered healthcare leaders throughout the nation, NRC Health
G1 tanks after placebo beats drug in cancer response rate test
[ad_1] G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo towards a number of efficacy measures in section 2. Trilaciclib carried out nicely towards its neutropenia-related major endpoints however fell brief in phrases of response rate, prompting traders to ship G1's stock down 26%. North Carolina-based G1 designed the section 2 to evaluate
Here's What To Look For From The Upcoming VBI Vaccines, Inc. – Ordinary Shares (NASDAQ:VBIV) Phase III Study
[ad_1] VBI Vaccines, Inc. – Ordinary Shares (NASDAQ:VBIV) simply introduced the main points of its lengthy awaited part III program in hepatitis B. The program, if profitable, will underpin registration purposes for VBI’s lead hepatitis B asset within the US, Europe and Canada and – as such – its initiation is a significant step in ...
4 Facts About Using Genetics in Pursuit of a More Perfect Christmas Tree
[ad_1] What will your Christmas items be positioned beneath this yr? A Fraser fir? A Douglas fir? An synthetic tree? While some people love the look and odor of a actual Christmas tree, others desire the low maintenance and longevity of a man-made tree. But what if we might use genetics to enhance the Christmas ...
Galectin Therapeutics Announces Extension of $10 Million Line Credit Nasdaq:GALT
NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the main developer of therapeutics that focus on galectin proteins, as we speak introduced that its $10 million unsecured line of credit score entered into on December 19, 2017, has been prolonged by one yr for each borrowings and maturity. The line ...
Apellis says timeline still on track for stalled eye drug
[ad_1] Apellis says will probably be capable of restart two trials of its APL-2 drug for eye illness geographic atrophy (GA) subsequent 12 months, after discovering the reason for unintended effects that introduced this system to a halt. Enrollment was halted within the DERBY and OAKS trials in October after noninfectious irritation was seen in ...
ESPR Esperion Therapeutics, Inc. Consolidation (NASDAQ:ESPR)
[ad_1] (NASDAQ:ESPR) Esperion Therapeutics Inc (NASDAQ:ESPR) Esperion Therapeutics, Inc. peaked out and closed at $48.90, manner up from about $10 the place it sat final August, however manner beneath its all-time excessive of $107.51 in spring 2015. Still, ESPR has been on a very good run since about January, however particularly since June, most ...
BIO Illustrates the Success of the Orphan Drug Act
[ad_1] The numbers may shock you. Approximately 7,000 uncommon ailments are identified to exist, and roughly 30 new ones are recognized every year. Also generally known as orphan ailments, they're outlined as these which have an effect on fewer than 200,000 sufferers in America. And whereas it may be true that every uncommon illness solely ...
Amgen pays $50M for Molecular Partners’ preclinical Anti-cancer
Amgen is paying Molecular Partners $50 million (€44 million) upfront for world rights to preclinical anti-cancer immune cell activator MP0310. The companions will take a look at the 4-1BB-FAP bispecific molecule together with Amgen medicine together with its bispecific T-cell engagers. Antibodies focusing on T cell co-stimulatory receptor 4-1BB, also referre
CRYO American CryoStem Corp Continues, but is it time to SELL?
[ad_1] OTC:CRYO (American CryoStem Corporation), primarily based in Eatontown, NJ, with associate laboratories within the U.S., Japan and China, is a firm engaged in growing, bringing to market, standardizing and licensing applied sciences, supplies and companies geared at adipose tissue (aka physique fats) regenerative and personalised drugs. In this capa
Road to 2018 Farm Bill Was Years in the Making
[ad_1] Contrary to some beliefs, the Farm Bill helps extra than simply America’s agriculture sector. The invoice’s power title packages present important help to corporations and producers engaged on improvements in renewable chemical compounds, superior biofuels and different merchandise of business biotechnology all through the worth chain. And these appli
Hernia Surgeon Discusses Surgery Costs in Los Angeles
[ad_1] David Albin, MD and Michael Albin, MD – Hernia Surgeons in Los Angeles Los Angeles Hernia Surgeons Dr. David Albin and Dr. Michael Albin Hernia Center of Southern California LOS ANGELES, Dec. 18, 2018 (GLOBE NEWSWIRE) — A hernia is a situation in which an organ pushes by way of a gap or tear ...
How neurons fend off Alzheimer’s with a cellular broom that clears the toxic tau protein
[ad_1] When the protein tau builds up inside the neurons of the mind, the cells grow to be impaired and ultimately die in a course of that’s been implicated in Alzheimer’s and different neurodegenerative ailments. But some neurons by no means get clogged up with tau—and a workforce of scientists led by the Columbia University ...
From Disease to Looming Food Crisis, Gene Editing Could Unlock Solutions to Our Greatest Problems
[ad_1] Today, celiac illness impacts one in 100 folks worldwide, and with no remedy, the one therapy is a gluten-free weight-reduction plan. However, scientists at the moment are exploring how gene modifying expertise, like CRISPR, may modify the protein of wheat in order that these with celiac illness may get pleasure from meals that sometimes ...
The Cancer Research Collaboration Partners with Diabetes Prevention Program Provider Blue Mesa Health with California Residents in Mind Nasdaq:RDNT
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — The Cancer Research Collaboration (CRC), a non-profit group devoted to increasing the supply of cutting-edge most cancers analysis, in partnership with RadNet, Inc. (Nasdaq:RDNT), a nationwide market chief offering high-quality, cost-effective diagnostic imaging providers by a community of fully-owned and oper
BIO Supports Renegotiated U.S. Japan Trade Agreement
[ad_1] BIO helps the U.S. Trade Representative’s (USTR) negotiations with the Government of Japan as a possibility to develop U.S. exports and create U.S. jobs. We would strongly urge the U.S. authorities to construct on the latest U.S.-Mexico-Canada settlement and that the settlement comprehensively addresses the biotechnology sector as an engine for progre
Bellicum reports first data on ‘controllable’ CAR-T
[ad_1] Bellicum Pharma has the first data on BPX-601, its first CAR-T with a built-in activation change to spice up its results, and says preliminary outcomes present indicators of biologic exercise. Data from 12 sufferers enrolled in a section 1/2 dose-escalation examine in PSCA-positive metastatic pancreatic most cancers handled with the CAR-T confirmed th
.jpg&w=3840&q=75)
Sensorion’s vertigo drug hits tolerability endpoint in phase 2
[ad_1] A phase 2a trial of Sensorion’s vertigo seliforant has met its major tolerability endpoint. The trial discovered the histamine kind 4 receptor antagonist had no impact on vigilance and cognitive efficiency, suggesting it could have an edge over present vertigo remedies comparable to meclizine. Meclizine, a histamine H1 receptor antagonist, is used to
.jpg&w=3840&q=75)
Axovant buys more gene therapies, setting it up for a busy 2019
[ad_1] Axovant has licensed two gene therapies from the University of Massachusetts Medical School (UMMS). The deal accelerates Axovant’s evolution into a gene remedy specialist by giving it management of two belongings which might be in or close to the clinic. Following the failures of intepirdine and nelotanserin, Axovant purged its pipeline of small molec
Extendicare Announces December 2018 Dividend of C$0.04 per Share Toronto Stock Exchange:EXE
[ad_1] MARKHAM, Ontario, Dec. 13, 2018 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) introduced that it has declared a money dividend of C$0.04 per frequent share of the Company (the “Common Share”) for the month of December 2018, which is payable on January 15, 2019 to shareholders of file on the ...
CRISPR controls obesity in mice by amplifying rather than editing genes
[ad_1] The genes SIM1 and MC4R regulate food consumption by signaling the sensation of being full, which is why mutations in these genes are related to extreme obesity. Even if simply one of many two copies of these genes {that a} person inherits from each dad and mom is unhealthy, she or he will most ...
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint
[ad_1] Sunovion Pharmaceuticals and PsychoGenics unveiled constructive phase 2 outcomes for a brand new schizophrenia therapy that doesn't bind to the mind’s dopamine receptors. While its precise mechanism of motion is unknown, the 2 firms imagine that SEP-363856 prompts hint amine-associated receptor 1 (TAAR1) along with the serotonin receptor 5-HT1A with o
Nobel Prize-Winning Chemists: Misguided GMO Fears Could Hinder Technology’s Societal Benefits
[ad_1] On Friday, December 7, two winners of the 2018 Nobel prize for Chemistry – American chemical engineer Frances Arnold and British biochemist Sir Gregory Winter – expressed concern that misguided fears about genetically modified (GM) meals might hinder the various societal advantages the know-how gives and curtail necessary scientific developments. Acco
Deep Blue Med Spa Announces New Profound Procedure to Treat Wrinkles and Rejuvenate Jawline
[ad_1] LONG ISLAND, NY, Dec. 13, 2018 (GLOBE NEWSWIRE) — Deep Blue Med Spa, overseen by the plastic surgeons at Long Island Plastic Surgical Group, is happy to announce the addition of Profound, a singular microneedling radiofrequency therapy, to its vary of rejuvenating remedies and beauty procedures at places in Garden City, East Hills, Babylon, ...
Amag merges with Perosphere, adding NOAC antidote
[ad_1] Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its rising hematology enterprise. The phrases of the deal see Amag making an upfront cost of $50 million for privately-held Perosphere, assuming $18.5 million of its debt and different liabilities, and committing to pay as much ...
.jpg&w=3840&q=75)
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
[ad_1] NeuroRx is planning to maneuver NRX-101 into part 2b/3 after detecting indicators of efficacy in a feasibility trial in patients with suicidal bipolar depression. The small part 2 feasibility research linked fixed-dose mixture NRX-101 to improved scores on a depression ranking scale. Delaware-based NeuroRx primarily designed the trial to evaluate blo
Biogen bails on AGTC after ocular gene therapy flunks trial
[ad_1] Applied Genetic Technologies’ $1 billion-plus gene therapy pact with Biogen has been torn up after their lead candidate failed a part 1/2 trial. Six-month data from the examine of rAAV2tYF-CB-hRS1 in sufferers with an inherited retinal dysfunction referred to as X-linked retinoschisis (XLRS)—the centrepiece of the 2 firms' 2015 collaboration—confirmed
Could a once-abandoned obesity drug be revived in osteoporosis?
[ad_1] Irisin, the as soon as much-hyped however controversial “exercise hormone” that researchers had hoped would be an efficient obesity remedy, might make a comeback—this time in bone strengthening. In a examine revealed in the journal Cell, a staff led by scientists at Harvard University Medical School discovered that injections of irisin in mice elevat
Biofrontera cleared of wrongdoing in Nasdaq IPO
[ad_1] An impartial evaluation has cleared Biofrontera of wrongdoing associated to its U.S. IPO. Shareholders had accused Biofrontera of appearing opposite to its duties when it priced and bought stock in the U.S. Biofrontera, which was elevating cash to run dermatological scientific trials, rejected the accusations however labored with a company that repres
FDA hails 2018 as bumper year for drug development successes
[ad_1] The FDA has hailed 2018 as a standout year for drug development and approvals, each by way of the amount and high quality of exercise. With the FDA approving 55 new molecular entities (NMEs) over the primary 11 months of the year, 2018 has eased previous 1996 to turn into the busiest year ever. ...
Interactive Map Displays Strength of Industry’s National Footprint
[ad_1] BIO’s biennial financial growth and jobs report focuses on the financial progress and nationwide footprint of the bioscience business. As the business’s go-to useful resource for efficiency, positioning and traits, this necessary reference device for advocacy and messaging demonstrates the worth of the business’s constant file of producing high-qualit
GenSight rebuilds its case for LHON gene therapy, eyeing filing next year
[ad_1] GenSight Biologics has reported new knowledge from its section 3 program for GS010, its gene remedy for an ultrarare eye illness, sparking one other uptick in its share value. The French biotech says the newest outcomes from its REVERSE trial of GS010 (rAAV2-ND4) in Leber hereditary optic neuropathy (LHON) present quality-of-life advantages in suffere
BIO Hosts Embassy Briefing on International Economic Development
[ad_1] Last week BIO hosted embassy representatives from over 25 international locations to debut a brand new report that highlights methods, insurance policies and finest practices which have been profitable in creating an surroundings during which biotechnology innovation can flourish all over the world. The fifth version of the Building the Bioeconomy rep
HEALTH FOUNDATION OF SOUTH FLORIDA NAMES NEW POLICY AND PUBLIC AFFAIRS DIRECTOR
[ad_1] Natalie Ok. Castellanos, JD MIAMI, FL, Dec. 11, 2018 (GLOBE NEWSWIRE) — Health Foundation of South Florida, the biggest philanthropy devoted to bettering health in Broward, Miami-Dade and Monroe Counties, has named Natalie Ok. Castellanos, JD as Director, Policy and Public Affairs. In this new place, she is going to work intently with Health ..
National Research Corporation Declares Special and Quarterly Dividend Nasdaq:NRC
[ad_1] NRC Logo NRC brand National Research Corporation Lincoln, Nebraska, Dec. 10, 2018 (GLOBE NEWSWIRE) — image002National Research Corporation (NASDAQ:NRC) right this moment introduced that its Board of Directors has declared a particular dividend of fifty cents ($0.50) per share to shareholders of document as of the shut of enterprise on Monday, D
Franciscan Health Doctor Named Purdue Athletics Head Team Physician
[ad_1] Carly-Day Dr. Carly Day, a member of Franciscan Physician Network, has been appointed Head Team Physician of Purdue University athletics and can oversee all points of medical care for greater than 500 student-athletes. Franciscan Health WEST LAFAYETTE, Indiana , Dec. 10, 2018 (GLOBE NEWSWIRE) — Purdue University’s athletic squads have a brand ne
The Administration’s Orwellian Defense of Importing Foreign Price Controls
[ad_1] The Trump administration is out with a new blog post defending its plan to undertake international value controls for medicines coated underneath Medicare Part B. The weblog was written within the wake of growing backlash from free-market thought leaders who're difficult the administration’s draconian proposal. The newest weblog put up from the Depart
LHC Group and LifePoint Health expand partnership with two acquisitions in North Carolina and Virginia Nasdaq:LHCG
[ad_1] LAFAYETTE, La., Dec. 10, 2018 (GLOBE NEWSWIRE) — LHC Group (NASDAQ: LHCG) and LifePoint Health® right this moment introduced the continued growth of their partnership. The corporations have finalized two transactions to buy and share possession of residence health service suppliers in Hickory, N.C., and Danville, Va. LHC Group and LifePoint fash
Beyond Labels: 10 Things You Should Know About GMOs
[ad_1] As the brand new federal guidlines for disclosure of bioengineered meals (within the type of the National Bioengineered Food Disclosure Law) are anticipated to be introduced quickly, let’s check out what you really want to find out about genetically modified organisms, genetically modified crops, and genetically modified meals. Walk into any grocery r
Global Carbon Project Reports 2018 Record Year for Carbon Emissions. Airlines Look To Change That
[ad_1] In a trio of scientific papers launched by the Global Carbon Project at a local weather summit in Poland, the Project’s researchers report that in 2018 global emissions of carbon dioxide reached the highest levels on record. The report flies within the face of presumed progress that has been made since local weather change grew to become ...
Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio
[ad_1] During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a dialogue about innovation happening in the biopharma business, the price and worth of prescription medicines and how the latest midterm elections might influence the drug pricing debate. “The latest indications are that for every $1 we ...
Advaxis Inc (NASDAQ:ADXS) Forms Global Agreement with Amgen
Advaxis Inc (NASDAQ:ADXS) shares were up 6.24% on Monday and down 0.99% in after-hours trading after announcing its global agreement with Amgen. The company has a market cap of $577 million at 34.35 million shares outstanding. Share prices have been trading in a 52-week range of $5.21 to $22.20. Advaxis Inc is a clinical-stage biotechnology company...
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Set to Gain on Lead Candidate Data Presentation
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE), a Texas based development stage biotech company, just gave us an update regarding its intentions to report (present) data at an upcoming conference. The data, which relates to its early stage oncology candidate AEB1102, will hit press as part of a scientific poster session at the Annual Meeting of the...
What's Going On With Biotech Stocks 2018? Here's what we know…
Intro & History on ABBV (NYSE:ABBV) : In the biotech and medical marijuana arena, we think that ABBV AbbVie Inc. (NYSE ABBV) is an interesting and well known stock to keep an eye on. ABBV is a pharmaceutical development, discovery, manufacturing and sales firm based in Illinois near Chicago, and… We think Cara Therapeutics...